Need Help? Chat Online or Toll Free: 1-800-891-0844
Cart (0)

Ebglyss (Lebrikizumab)

What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.

Coming Soon – Save up to 85%

Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.

Sign Up

Prescription Required

  • Related Products & Conditions

  • Product Details

    Description

    Ebglyss (lebrikizumab) is a humanized monoclonal antibody that selectively binds to interleukin-13 (IL-13), a key cytokine involved in the pathophysiology of atopic dermatitis (AD). By blocking IL-13 signaling, Ebglyss reduces inflammation, skin barrier dysfunction, and pruritus associated with moderate to severe atopic dermatitis. It is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Ebglyss can be used with or without topical corticosteroids.

    Fact Table

    Formula

    C6412H9896N1712O2004S46

    License

    US FDA (2023), EMA (2024)

    Bioavailability

    ~85% (subcutaneous)

    Legal status

    Rx-only

    Chemical Name

    Lebrikizumab

    Elimination half-life

    ~25–30 days

    Dosage (Strength)

    150 mg/1 mL prefilled syringe or autoinjector

    Pregnancy

    Use only if clearly needed; human data lacking

    Brands

    Ebglyss

    Protein binding

    Not applicable (monoclonal antibody)

    PubChem CID

    250774857

    MedlinePlus

    Not yet assigned

    ChEBI

    Not available

    ATC code

    D11AH07

    DrugBank

    DB12030

    KEGG

    D12189

    Routes of administration

    Subcutaneous

    Directions

    Ebglyss is administered as a subcutaneous injection.

    Loading dose: 500 mg (two 250 mg injections) at Week 0 and Week 2

    Maintenance dose: 250 mg every two weeks thereafter

    Ebglyss should be administered by a healthcare provider or by the patient/caregiver if properly trained. Injection sites should be rotated with each dose. It can be used with or without concomitant topical corticosteroids or other topical agents.

    Ingredients

    Active Ingredient: Lebrikizumab

    Inactive Ingredients: Acetic acid, polysorbate 80, sodium acetate trihydrate, sodium chloride, and water for injection. The formulation is preservative-free and provided as a sterile, ready-to-use solution.

    Contraindications

    Ebglyss is contraindicated in patients with:

    Known hypersensitivity to lebrikizumab or any of its excipients

    A history of anaphylaxis related to monoclonal antibody treatment

    Cautions

    Prior to initiating Ebglyss, patients should be evaluated for existing parasitic (helminth) infections, as IL-13 inhibition may impair host defense. Treatment should be withheld if a serious infection occurs until resolved. Avoid use with live vaccines during treatment. The safety and efficacy of Ebglyss have not been established in patients with other atopic or allergic conditions beyond atopic dermatitis.

    Side Effects

    Common side effects include:

    Conjunctivitis

    Injection site reactions

    Headache

    Increased eosinophil counts

    Less common or serious side effects may include:

    Hypersensitivity reactions

    Eye inflammation requiring ophthalmologic evaluation

    IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

    Product Code : 15193

  • Product Reviews